Want to see CRBU full AI Analyst Report?
Top Page
Caribou Biosciences
(NASDAQ:CRBU)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.54
▼(-67.58% Downside)
Action:Upgraded
Date:10/13/26
CRBU scores low primarily due to weak financial performance (large losses, negative gross profit, declining revenue, and significant cash burn) and strongly bearish technicals (price far below key moving averages with negative MACD). Valuation metrics provide limited support because the company is loss-making (negative P/E) and there is no dividend yield provided. The restructuring and shift toward strategic alternatives further increase uncertainty and weigh on the score.
Positive Factors
Genome-edited cell therapy platform
The CRISPR and chRDNA platform gives Caribou a differentiated technical foundation in engineered immune-cell therapies. Its allogeneic, off-the-shelf approach is designed to support broader scalability than individualized treatments, preserving strategic potential across oncology programs over the next several quarters.
Negative Factors
Program discontinuations and restructuring
Stopping development of two key allogeneic CAR-T programs represents a major reduction in the active clinical pipeline and interrupts the path toward commercial products. The broad restructuring, workforce reduction, contract changes, and strategic review also create substantial uncertainty around the company’s future operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Genome-edited cell therapy platform
The CRISPR and chRDNA platform gives Caribou a differentiated technical foundation in engineered immune-cell therapies. Its allogeneic, off-the-shelf approach is designed to support broader scalability than individualized treatments, preserving strategic potential across oncology programs over the next several quarters.
Read all positive factors
Caribou Biosciences (CRBU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$55.64M
Dividend YieldN/A
Average Volume (3M)4.06M
Price to Earnings (P/E)―
Beta (1Y)2.16
Revenue Growth10.02%
EPS Growth39.66%
CountryUS
Employees97
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.08
Shares Outstanding107,207,510
10 Day Avg. Volume9,314,876
30 Day Avg. Volume4,064,771
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue9.18
Enterprise Value/Gross Profit-7.07
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$3.75Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$9.17M
Caribou Biosciences Business Overview & Revenue Model
Company Description
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) an...
Caribou Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.04M | 11.16M | 9.99M | 34.48M | 13.85M | 9.60M |
| Gross Profit | -13.02M | 7.51M | 6.07M | 30.95M | 10.21M | 8.61M |
| EBITDA | -103.48M | -145.03M | -145.19M | -98.35M | -97.73M | -65.61M |
| Net Income | -103.40M | -148.13M | -149.10M | -102.07M | -99.42M | -66.92M |
Balance Sheet | ||||||
| Total Assets | 142.77M | 175.37M | 313.31M | 432.21M | 373.76M | 442.36M |
| Cash, Cash Equivalents and Short-Term Investments | 112.31M | 139.34M | 209.54M | 328.83M | 247.66M | 375.83M |
| Total Debt | 26.66M | 27.23M | 26.49M | 27.11M | 27.75M | 259.00K |
| Total Liabilities | 44.67M | 53.19M | 60.36M | 63.81M | 72.89M | 54.53M |
| Stockholders Equity | 98.10M | 122.17M | 252.95M | 368.40M | 300.87M | 387.82M |
Cash Flow | ||||||
| Free Cash Flow | -95.75M | -112.35M | -144.71M | -104.90M | -98.02M | -35.64M |
| Operating Cash Flow | -95.78M | -110.99M | -138.20M | -93.29M | -90.97M | -32.52M |
| Investing Cash Flow | 71.75M | 102.24M | 86.61M | -68.18M | -93.25M | -176.40M |
| Financing Cash Flow | 24.98M | 4.82M | 16.72M | 154.30M | 2.13M | 433.43M |
Caribou Biosciences Technical Analysis
Negative
1.65
Price Trends
1.21
Negative
1.46
Negative
1.67
Negative
Market Momentum
-0.22
Negative
26.66
Positive
79.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Negative. The current price of 1.65 is above the 20-day moving average (MA) of 0.79, above the 50-day MA of 1.21, and below the 200-day MA of 1.67, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 26.66 is Positive, neither overbought nor oversold. The STOCH value of 79.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBU.
Caribou Biosciences Risk Analysis
Caribou Biosciences disclosed 84 risk factors in its most recent earnings report. Caribou Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Caribou Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $272.97M | -0.97 | -128.27% | ― | ― | 41.56% | |
42 Neutral | $45.24M | -0.78 | -1266.43% | ― | ― | 49.43% | |
41 Neutral | $55.64M | -0.50 | -89.11% | ― | 10.02% | 39.66% | |
41 Neutral | $1.13B | -0.06 | -91.63% | ― | ― | 69.48% | |
38 Underperform | $80.83M | -1.71 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
CRBU
Caribou Biosciences
0.56
-1.94
-77.60%
CLLS
Cellectis SA
0.98
-2.50
-71.90%
CABA
Cabaletta Bio
1.52
-0.89
-36.93%
ELTX
Elicio Therapeutics
1.94
-7.56
-79.58%
VOR
Vor Biopharma
18.94
-8.82
-31.77%
Caribou Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Caribou Biosciences announces restructuring, explores strategic alternatives
Negative
Oct 6, 2026
On October 2, 2026, Caribou Biosciences’ board approved a broad restructuring as it begins evaluating strategic alternatives, including possible mergers, acquisitions, or other transactions to maximize shareholder value. As part of this move...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.